Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Linavonkibart, also known as SRK-181, is a fully human IgG4 monoclonal antibody designed to selectively inhibit the latent transforming growth factor-beta isoform 1 (TGFB1). Transforming growth factor-B1 (TGF-B1) is a key member of the TGF-beta family, a group of evolutionarily conserved polypeptide growth factors. The gene encoding TGF-B1 is located on chromosome 19 at the 19q13.2 locus. Structurally, TGF-B1 is synthesized as a precursor, which is then cleaved to produce a mature polypeptide that forms a dimeric protein. Functionally, TGF-B1 plays a crucial role in cellular processes such as proliferation, differentiation, and apoptosis, and is essential for regulating immune responses, maintaining tissue homeostasis, and orchestrating wound healing. Dysregulation of TGF-B1 signaling has been implicated in various pathological conditions including cancer, fibrosis, and autoimmune disorders. The activation of latent TGF-B1 stored in the extracellular matrix is mediated by interaction with integrins and other co-factors that induce conformational changes necessary for its biological activity.
仅用于科研。不用于诊断过程。未经明确授权不得转售。